Literature DB >> 26831716

Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation.

Mohammad Hedayati1, Michael C Haffner2, Jonathan B Coulter1, Raju R Raval1, Yonggang Zhang1, Haoming Zhou1, Omar Mian1, Emma J Knight1, Nina Razavi1, Susan Dalrymple2, John T Isaacs2, Aileen Santos1, Russell Hales1, William G Nelson1,2, Srinivasan Yegnasubramanian2, Theodore L DeWeese1,2.   

Abstract

PURPOSE: The current standard of care for patients with locally advanced prostate cancer is a combination of androgen deprivation and radiation therapy. Radiation is typically given with androgen suppression when testosterone levels are at their nadir. Recent reports have shown that androgen stimulation of androgen-deprived prostate cancer cells leads to formation of double-strand breaks (DSB). Here, we exploit this finding and investigate the extent and timing of androgen-induced DSBs and their effect on tumor growth following androgen stimulation in combination with ionizing radiation (IR). EXPERIMENTAL
DESIGN: Androgen-induced DNA damage was assessed by comet assays and γH2A.X foci formation. Effects of androgen stimulation and radiation were determined in vitro and in vivo with xenograft models.
RESULTS: We document that androgen treatment of androgen-deprived prostate cancer cell lines resulted in a dose- and time-dependent induction of widespread DSBs. Generation of these breaks was dependent on androgen receptor and topoisomerase II beta but not on cell-cycle progression. In vitro models demonstrated a synergistic interaction between IR and androgen stimulation when IR is given at a time point corresponding with high levels of androgen-induced DSB formation. Furthermore, in vivo studies showed a significant improvement in tumor growth delay when radiation was given shortly after androgen repletion in castrated mice.
CONCLUSIONS: These results suggest a potential cooperative effect and improved tumor growth delay with androgen-induced DSBs and radiation with implications for improving the therapeutic index of prostate cancer radiation therapy. Clin Cancer Res; 22(13); 3310-9. ©2016 AACRSee related commentary by Chua and Bristow, p. 3124. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26831716      PMCID: PMC4930695          DOI: 10.1158/1078-0432.CCR-15-1147

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  34 in total

1.  A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription.

Authors:  Bong-Gun Ju; Victoria V Lunyak; Valentina Perissi; Ivan Garcia-Bassets; David W Rose; Christopher K Glass; Michael G Rosenfeld
Journal:  Science       Date:  2006-06-23       Impact factor: 47.728

2.  Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer.

Authors:  Michael J Morris; Daisy Huang; William K Kelly; Susan F Slovin; Ryan D Stephenson; Caitlin Eicher; Anthony Delacruz; Tracy Curley; Lawrence H Schwartz; Howard I Scher
Journal:  Eur Urol       Date:  2009-04-03       Impact factor: 20.096

3.  Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer.

Authors:  John T Isaacs; Jason M D'Antonio; Shuangling Chen; Lizamma Antony; Susan P Dalrymple; Georges H Ndikuyeze; Jun Luo; Samuel R Denmeade
Journal:  Prostate       Date:  2012-03-06       Impact factor: 4.104

4.  Treatment of locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery.

Authors:  M E Lippman; R A Sorace; C S Bagley; D W Danforth; A Lichter; M N Wesley
Journal:  NCI Monogr       Date:  1986

5.  Estrogen receptor α-mediated transcription induces cell cycle-dependent DNA double-strand breaks.

Authors:  Laura M Williamson; Susan P Lees-Miller
Journal:  Carcinogenesis       Date:  2010-11-26       Impact factor: 4.944

Review 6.  The AR dependent cell cycle: mechanisms and cancer relevance.

Authors:  Matthew J Schiewer; Michael A Augello; Karen E Knudsen
Journal:  Mol Cell Endocrinol       Date:  2011-07-12       Impact factor: 4.102

7.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Authors:  Anders Widmark; Olbjørn Klepp; Arne Solberg; Jan-Erik Damber; Anders Angelsen; Per Fransson; Jo-Asmund Lund; Ilker Tasdemir; Morten Hoyer; Fredrik Wiklund; Sophie D Fosså
Journal:  Lancet       Date:  2008-12-16       Impact factor: 79.321

8.  A role of DNA-PK for the metabolic gene regulation in response to insulin.

Authors:  Roger H F Wong; Inhwan Chang; Carolyn S S Hudak; Suzanne Hyun; Hiu-Yee Kwan; Hei Sook Sul
Journal:  Cell       Date:  2009-03-20       Impact factor: 41.582

9.  Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation.

Authors:  Daniel E Spratt; Michael J Evans; Brian J Davis; Michael G Doran; Man Xia Lee; Neel Shah; John Wongvipat; Kathryn E Carnazza; George G Klee; William Polkinghorn; Donald J Tindall; Jason S Lewis; Charles L Sawyers
Journal:  Cancer Res       Date:  2015-10-02       Impact factor: 12.701

10.  Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome.

Authors:  Damien A Leach; Eleanor F Need; Roxanne Toivanen; Andrew P Trotta; Helen M Palethorpe; Helen M Palenthorpe; David J Tamblyn; Tina Kopsaftis; Georgina M England; Eric Smith; Paul A Drew; Carole B Pinnock; Peng Lee; Jeff Holst; Gail P Risbridger; Samarth Chopra; Donald B DeFranco; Renea A Taylor; Grant Buchanan
Journal:  Oncotarget       Date:  2015-06-30
View more
  17 in total

1.  Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer.

Authors:  Liana B Guedes; Fawaz Almutairi; Michael C Haffner; Gaurav Rajoria; Zach Liu; Szczepan Klimek; Roberto Zoino; Kasra Yousefi; Rajni Sharma; Angelo M De Marzo; George J Netto; William B Isaacs; Ashley E Ross; Edward M Schaeffer; Tamara L Lotan
Journal:  Clin Cancer Res       Date:  2017-04-26       Impact factor: 12.531

Review 2.  The structure of the nucleus in normal and neoplastic prostate cells: untangling the role of type 2 DNA topoisomerases.

Authors:  William G Nelson; Michael C Haffner; Srinivasan Yegnasubramanian
Journal:  Am J Clin Exp Urol       Date:  2018-04-01

3.  Molecular determinants of response to high-dose androgen therapy in prostate cancer.

Authors:  Michael D Nyquist; Alexandra Corella; Osama Mohamad; Ilsa Coleman; Arja Kaipainen; Daniel A Kuppers; Jared M Lucas; Patrick J Paddison; Stephen R Plymate; Peter S Nelson; Elahe A Mostaghel
Journal:  JCI Insight       Date:  2019-10-03

4.  Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer.

Authors:  Michael T Schweizer; Emmanuel S Antonarakis; Samuel R Denmeade
Journal:  Eur Urol       Date:  2017-03-29       Impact factor: 20.096

5.  Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.

Authors:  Payel Chatterjee; Michael T Schweizer; Jared M Lucas; Ilsa Coleman; Michael D Nyquist; Sander B Frank; Robin Tharakan; Elahe Mostaghel; Jun Luo; Colin C Pritchard; Hung-Ming Lam; Eva Corey; Emmanuel S Antonarakis; Samuel R Denmeade; Peter S Nelson
Journal:  J Clin Invest       Date:  2019-07-16       Impact factor: 14.808

6.  Susceptibility of ATM-deficient pancreatic cancer cells to radiation.

Authors:  Michael Ayars; James Eshleman; Michael Goggins
Journal:  Cell Cycle       Date:  2017-04-28       Impact factor: 4.534

7.  Rationale for bipolar androgen therapy (BAT) for metastatic prostate cancer.

Authors:  John T Isaacs; W Nathaniel Brennen; Samuel R Denmeade
Journal:  Cell Cycle       Date:  2017-08-18       Impact factor: 4.534

8.  Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.

Authors:  Michael D Nyquist; Lisa S Ang; Alexandra Corella; Ilsa M Coleman; Michael P Meers; Anthony J Christiani; Cordell Pierce; Derek H Janssens; Hannah E Meade; Arnab Bose; Lauren Brady; Timothy Howard; Navonil De Sarkar; Sander B Frank; Ruth F Dumpit; James T Dalton; Eva Corey; Stephen R Plymate; Michael C Haffner; Elahe A Mostaghel; Peter S Nelson
Journal:  J Clin Invest       Date:  2021-05-17       Impact factor: 14.808

9.  Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155.

Authors:  Michael D Nyquist; Alexandra Corella; John Burns; Ilsa Coleman; Shuai Gao; Robin Tharakan; Luke Riggan; Changmeng Cai; Eva Corey; Peter S Nelson; Elahe A Mostaghel
Journal:  Mol Cancer Res       Date:  2017-05       Impact factor: 6.333

10.  Olaparib is effective in combination with, and as maintenance therapy after, first-line endocrine therapy in prostate cancer cells.

Authors:  Gertrud E Feiersinger; Kristina Trattnig; Peter D Leitner; Fabian Guggenberger; Alexander Oberhuber; Sarah Peer; Martin Hermann; Ira Skvortsova; Jana Vrbkova; Jan Bouchal; Zoran Culig; Frédéric R Santer
Journal:  Mol Oncol       Date:  2018-03-15       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.